Praecis Abarelix Slated To Enter Phase III For Prostate Cancer In 1998
Executive Summary
Praecis' lead compound abarelix is poised to enter Phase III trials for prostate cancer this year, Praecis CEO Malcolm Gefter told a Nationsbanc Montgomery Securities investor conference in New York City July 15.